The prevention of diabetes and cardiovascular disease in people with schizophrenia
Abstract
Objective: Primary prevention of diabetes and cardiovascular disease is an important priority for people with schizophrenia. This review aims to identify lifestyle and pharmacological interventions that reduce diabetes and cardiovascular disease in people with schizophrenia. Method: PubMed and other electronic databases were searched to identify relevant articles. Results: Lifestyle interventions that focus on diet and physical activity reduce the incidence of diabetes. Similar programmes in people with schizophrenia have led to significant weight loss and may reasonably be expected to reduce diabetes in the long‐term. Metformin may be considered when lifestyle change is not feasible or effective. Lifestyle interventions, particularly smoking cessation, are likely to be effective in reducing cardiovascular disease in people with schizophrenia. Although cardiovascular prevention trials with statins have not been performed in people with schizophrenia, similar reductions in cholesterol has been seen as in the general population and statins should be considered for those at high risk. Traditional cardiovascular risk prediction models perform well in identifying those at high cardiovascular risk, but bespoke prediction models using data from people with schizophrenia perform better. Conclusion: Reducing diabetes and cardiovascular disease requires a coordinated and concerted effort from mental and physical health teams working across primary and secondary care.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many people with mental ill health are not offered timely treatment even after an established diagnosis of T2DM is made.
“Even after an established diagnosis of T2DM is made, many of those with mental ill health are not offered timely treatment 42”
From Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016) · cites this paper as [42]
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 5× · see citing works
“52) (21) Indian Diabetes Prevention Study 531 IGT Diet and physical activity 2.”
BackgroundInfluentialTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2× · see citing works
“Building on the epidemiological evidence relating potentially modifiable environmental factors to type 2 diabetes, over the last 16 years, a number of randomised controlled trials from China (19), Finland (20), USA (21), India (22) and Japan (23) have demonstrated beyond doubt that lifestyle modification can prevent,…”
BackgroundPan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320 · see citing works
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · see citing works
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · see citing works
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · see citing works
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · see citing works
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881 · see citing works
Wilmot, E. G., Edwardson, C. L., Achana, F. A., Davies, M. J., Gorely, T., Gray, L. J., Khunti, K., Yates, T., & Biddle, S. J. H. (2012) · Diabetologia · doi:10.1007/s00125-012-2677-z · Cited by 1,789 · see citing works
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · see citing works
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600 · see citing works
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 1,321 · see citing works
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276 · see citing works
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Self-citationExcess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · cited 2× · see citing works
“Cardiovascular morbidity and mortality are increased approximately 2- to 3-fold overall in people with schizophrenia (1, 2).”
BackgroundCarey, V. J., Walters, E. E., Colditz, G. A., Solomon, C. G., Willet, W. C., Rosner, B. A., Speizer, F. E., & Manson, J. E. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009158 · Cited by 827 · see citing works
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 752 · cited 2× · see citing works
“Several pharmacological interventions from two groups, one using drugs that are currently used to treat diabetes, including metformin (21, 22), acarbose (30) and thiazolinediones (31, 32) and the other using drugs for obesity, primarily orlistat (33), have been shown to reduce the incident diabetes (Table 2).”
BackgroundRummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
Osborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.242 · Cited by 608 · see citing works
Ali, M. K., Echouffo-Tcheugui, J. B., & Williamson, D. F. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1009 · Cited by 594 · see citing works
Diet, smoking and cardiovascular risk in people with schizophrenia
McCreadie, R. G., & Scottish Schizophrenia Lifestyle Group (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.6.534 · Cited by 494 · see citing works
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477 · see citing works
Diet, smoking and cardiovascular risk in people with schizophrenia
McCreadie, R. G., & Scottish Schizophrenia Lifestyle Group (2003) · The British Journal of Psychiatry · doi:10.1192/03-162 · Cited by 392 · see citing works
Mitchell, A. J., Malone, D., & Carney, C. P. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.045732 · Cited by 359 · see citing works
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332 · see citing works
Mitchell, A. J., Vancampfort, D., Herdt, A. D., Yu, W., & Hert, M. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 331 · see citing works
Vancampfort, D., Wampers, M., Mitchell, A. J., Correll, C. U., Herdt, A. D., Probst, M., & Binder, M. D. (2013) · World Psychiatry · doi:10.1002/wps.20069 · Cited by 320 · see citing works
Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia
Spelman, L., Walsh, P., Sharifi, N., Collins, P. B., & Thakore, J. H. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02092.x · Cited by 318 · see citing works
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304 · see citing works
Gillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., & Khunti, K. K. (2008) · BMJ · doi:10.1136/bmj.39545.585289.25 · Cited by 290 · see citing works
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., Hert, M. D., & Correll, C. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 281 · see citing works
Saito, T. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.275 · Cited by 277 · see citing works
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274 · see citing works
Self-citationLifestyle Interventions Reduce Coronary Heart Disease Risk
Maruthur, N. M., Wang, N., & Appel, L. J. (2009) · Circulation · doi:10.1161/circulationaha.108.809491 · Cited by 244 · see citing works
Norris, S. L., Kansagara, D. L., Bougatsos, C., & Fu, R. F. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 226 · see citing works
Osborn, D. P., Wright, C. A., Levy, G., King, M. B., Deo, R., & Nazareth, I. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-84 · Cited by 208 · see citing works
Antipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208 · see citing works
Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., & Uchida, H. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu030 · Cited by 203 · see citing works
Osborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200 · see citing works
Self-citationGray, L. J., Taub, N. A., Khunti, K. K., Gardiner, E., Hiles, S., Webb, D. R., Srinivasan, B. T., & Davies, M. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03037.x · Cited by 196 · see citing works
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182 · see citing works
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 181 · see citing works
Self-citationObesity, serious mental illness and antipsychotic drugs
Holt, R. I. G., & Peveler, R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01038.x · Cited by 161 · see citing works
Self-citationTemporal Trends in the Population Attributable Risk for Cardiovascular Disease
Cheng, S. C., Claggett, B. L., Correia, A. W., Shah, A. M., Gupta, D. K., Skali, H., Ni, H., Rosamond, W. D., HEISS, G. M., Folsom, A. R., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008506 · Cited by 159 · see citing works
A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients
Barnes, T. R. E., Paton, C., Cavanagh, M.-R., Hancock, E., Taylor, D. M., & Health, O. B. O. T. U. P. O. F. M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm038 · Cited by 145 · see citing works
Statin Therapy for Primary Prevention of Cardiovascular Disease
Taylor, F. C., Huffman, M. D., & Ebrahim, S. B. J. (2013) · JAMA · doi:10.1001/jama.2013.281348 · Cited by 141 · see citing works
Schwingshackl, L., Dias, S., & HOFFMANN, G. E. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-130 · Cited by 133 · see citing works
Citrome, L., Holt, R. I. G., Walker, D. J., & Hoffmann, V. P. (2011) · Clinical Drug Investigation · doi:10.2165/11589060-000000000-00000 · Cited by 115 · see citing works
Self-citationMukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629.pub2 · Cited by 103 · see citing works
Mitchell, A. J., Vancampfort, D., Binder, M. D., & Stubbs, B. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.11.006 · Cited by 96 · see citing works
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64 · see citing works
Self-citationHow can we promote smoking cessation in people with schizophrenia in practice? A clinical overview
Stubbs, B., Vancampfort, D., Bobes, J., Hert, M. A. F. D., & Mitchell, A. J. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12412 · Cited by 59 · see citing works
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Hanssens, L., Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2007) · PubMed · doi:10.1097/yic.0b013e3280113d3b · Cited by 57 · see citing works
Hjorth, P., Davidsen, A. S., Kilian, R., & Skrubbeltrang, C. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12245 · Cited by 57 · see citing works
Tunaiji, H. A., Davis, J. C., Mackey, D. C., & Khan, K. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-469 · Cited by 46 · see citing works
Taylor, J., Cottrell, C., Chatterton, H. T., Hill, J., Hughes, R., Wohlgemuth, C. M., & Holt, R. I. G. (2012) · Diabetic Medicine · doi:10.1111/dme.12027 · Cited by 33 · see citing works
Self-citationSurvey of diabetes risk assessment tools: concepts, structure and performance
Thoopputra, T., Newby, D., Schneider, J., & Li, S. C. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2296 · Cited by 33 · see citing works
Intentional Weight Loss in Overweight and Obese Patients With Severe Mental Illness
Holt, R. I. G., Pendlebury, J., Wildgust, H. J., & Bushe, C. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05627gre · Cited by 32 · see citing works
Self-citationGrande, E. D., Gill, T. K., Wyatt, L., et al. (2009) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2009.03.004 · Cited by 25 · see citing works
Considering metformin in cardiometabolic protection in psychosis
Curtis, J., Newall, H. D., Myles, N., Shiers, D., & Samaras, K. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01906.x · Cited by 18 · see citing works
Mukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629 · Cited by 11 · see citing works
Manu, P., Correll, C. U., Wampers, M., van Winkel, R., Yu, W., Mitchell, A. J., & Binder, M. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.002 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659 · see citing works
- Authors
- Holt, R. I. G.
- Affiliations
- Southampton General Hospital (GB)
- Corresponding author
- Holt, R. I. G.
- ORCID
- Holt, R. I. G.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2015-05-15
- Volume
- 132
- Issue
- 2
- Pages
- 86-96
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2118496502
- Cited by
- 37
- References
- 68
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2022: 6 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 1
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Psychiatrica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- schizophrenia, diabetes prevention, cardiovascular disease prevention, lifestyle intervention, diet, physical activity, weight loss, metformin, smoking cessation, statins, cardiovascular risk prediction models, primary prevention
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Diet, Health Promotion, Humans, Life Style, Risk Factors, Schizophrenia, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
